Scarica l'app Stockscreener
4.07
13.22%
-0.62
Dopo l'orario di chiusura:
4.09
0.02
+0.49%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché IOVA Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$4.69
Aprire:
$4.43
Volume 24 ore:
19.85M
Relative Volume:
1.32
Capitalizzazione di mercato:
$1.82B
Reddito:
$285.55M
Utile/perdita netta:
$-353.86M
Rapporto P/E:
-4.2838
EPS:
-0.9501
Flusso di cassa netto:
$-305.02M
1 W Prestazione:
-18.44%
1M Prestazione:
-2.16%
6M Prestazione:
+59.61%
1 anno Prestazione:
+58.37%
Intervallo 1D:
$4.02
$4.55
Intervallo di 1 settimana:
$4.02
$5.16
Portata 52W:
$1.76
$5.64
Iovance Biotherapeutics Inc Stock (IOVA) Company Profile
Nome
Iovance Biotherapeutics Inc
Settore
Industria
Telefono
(650) 260-7120
Indirizzo
825 INDUSTRIAL ROAD, SAN CARLOS
Compare IOVA vs VRTX, REGN, ARGX, RVMD, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
IOVA
Iovance Biotherapeutics Inc
|
4.07 | 2.19B | 285.55M | -353.86M | -305.02M | -0.9501 |
VRTX
Vertex Pharmaceuticals Inc
|
477.10 | 121.57B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
762.63 | 69.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
853.82 | 55.61B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
187.53 | 39.98B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
316.01 | 33.81B | 5.76B | 514.49M | 1.10B | 4.4813 |
Iovance Biotherapeutics Inc Stock (IOVA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-02-25 | Aggiornamento | Citizens | Mkt Perform → Mkt Outperform |
| 2025-07-15 | Downgrade | Goldman | Neutral → Sell |
| 2025-05-16 | Downgrade | UBS | Buy → Neutral |
| 2025-05-12 | Downgrade | Truist | Buy → Hold |
| 2025-05-09 | Downgrade | Citizens JMP | Mkt Outperform → Mkt Perform |
| 2024-10-24 | Iniziato | UBS | Buy |
| 2024-07-29 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2023-11-20 | Iniziato | Goldman | Buy |
| 2023-09-18 | Reiterato | Barclays | Overweight |
| 2023-05-30 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2023-03-27 | Ripresa | Wells Fargo | Equal Weight |
| 2023-01-27 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2022-12-09 | Downgrade | Goldman | Buy → Neutral |
| 2022-10-31 | Iniziato | Guggenheim | Neutral |
| 2022-08-18 | Ripresa | Wells Fargo | Equal Weight |
| 2022-01-28 | Aggiornamento | Stifel | Hold → Buy |
| 2021-12-07 | Ripresa | Cowen | Outperform |
| 2021-06-10 | Aggiornamento | JMP Securities | Mkt Perform → Mkt Outperform |
| 2021-05-20 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2021-05-19 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| 2021-05-19 | Downgrade | Stifel | Buy → Hold |
| 2021-05-03 | Iniziato | Truist | Buy |
| 2021-04-16 | Iniziato | Goldman | Buy |
| 2021-03-08 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2020-12-15 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2020-10-06 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2020-04-22 | Iniziato | Mizuho | Buy |
| 2020-03-04 | Iniziato | Barclays | Overweight |
| 2020-02-26 | Reiterato | H.C. Wainwright | Buy |
| 2020-02-26 | Reiterato | Oppenheimer | Outperform |
| 2019-12-18 | Iniziato | JMP Securities | Mkt Outperform |
| 2019-10-01 | Iniziato | Stifel | Buy |
| 2019-04-29 | Iniziato | Piper Jaffray | Overweight |
| 2019-02-28 | Reiterato | Chardan Capital Markets | Buy |
| 2019-02-07 | Iniziato | Robert W. Baird | Outperform |
| 2018-12-31 | Ripresa | B. Riley FBR | Buy |
| 2018-07-06 | Reiterato | Chardan Capital Markets | Buy |
| 2018-04-10 | Aggiornamento | B. Riley FBR, Inc. | Neutral → Buy |
| 2018-03-13 | Reiterato | B. Riley FBR, Inc. | Neutral |
| 2018-02-23 | Downgrade | B. Riley FBR, Inc. | Buy → Neutral |
| 2018-01-25 | Reiterato | H.C. Wainwright | Buy |
| 2017-11-01 | Reiterato | B. Riley FBR, Inc. | Buy |
Mostra tutto
Iovance Biotherapeutics Inc Borsa (IOVA) Ultime notizie
IOVA|Iovance Biotherapeutics Inc|Price:4.900|Chg%:-0.090 - TradingKey
Iovance Biotherapeutics Inc (IOVA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Iovance Biotherapeutics Inc (IOVA) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Iovance Biotherapeutics Inc (IOVA) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Iovance Biotherapeutics Inc Revenue Breakdown – BX:IOVA - TradingView
Iovance Biotherapeutics Inc (IOVA) Balance Sheet - TradingKey
Iovance Biotherapeutics Inc (IOVA) Income Statement - TradingKey
Iovance Biotherapeutics Inc Revenue Breakdown – MIL:1IOVA - TradingView
Iovance Shares Close Unchanged After Choppy Trading; 2026 Sales Target Puts Pressure on Growth Pace - TechStock²
Iovance Biotherapeutics Inc (IOVA) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
IOVA Stock Slump Takes Wall Street, Retail By Surprise — Here’s Why - Stocktwits
symbol__ Stock Quote Price and Forecast - CNN
Iovance Biotherapeutics (IOVA) Rallies On Undervalued Claims, Is The Market Still Missing Fair Value? - Sahm
Iovance Biotherapeutics Market Sentiment - Benzinga España
Iovance Biotherapeutics, Inc. (IOVA) Stock Analysis: Exploring a 71.54% Potential Upside in Biotech - DirectorsTalk Interviews
Iovance Biotherapeutics Inc (IOVA) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Iovance Biotherapeutics, Inc. (IOVA) Options Chain - Yahoo! Finance Canada
Iovance Biotherapeutics stock hits 52-week high at $5.64 By Investing.com - Investing.com South Africa
Iovance Biotherapeutics stock hits 52-week high at $5.64 - Investing.com
Iovance Biotherapeutics (IOVA) Stock Looks Fully Priced Despite Strong 117% Returns - Sahm
REPL Vs IOVA: FDA Decision Day Could Test Biotech Bulls’ Conviction On These Melanoma Plays - Stocktwits
10 Health Care Stocks With Whale Alerts In Today’s Session - Benzinga
Why Is IOVA Stock Falling Today? - Stocktwits
Iovance (NASDAQ:IOVA) advances 18% in a week, drawing attention to Amtagvi sales goals - TechStock²
Why Did IOVA Stock Gain Pre-Market Today? - Stocktwits
Iovance Biotherapeutics (NASDAQ:IOVA) shares jump 18% as Amtagvi sales test approaches - TechStock²
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - The Manila Times
Iovance Gives 17 New Employees Options That Vest Over 3 Years - Stock Titan
After IOVA Stock’s Best Day In 2 Years, Analyst Sees Over 300% Upside: Here’s Why - Stocktwits
Iovance shares surge as attention shifts to Amtagvi’s second-half sales target - TechStock²
$4.659 | Iovance Biotherapeutics, Inc. Common Stock (IOVA) Stock Price Today - Binance
ETFs Investing in Iovance Biotherapeutics Inc Stocks - TradingView
Iovance: The Worst May Be Behind This TIL Pioneer (Upgrading To Buy) (NASDAQ:IOVA) - Seeking Alpha
Iovance Biotherapeutics (NASDAQ:IOVA) jumps 18%, adding a cash balance to its market value - TechStock²
IOVA Stock Holds Range As Capital Plans And Hiring Ramp Up - StocksToTrade
Soft Tissue Sarcoma Market Set for Significant Growth at a CAGR of 7.9% During the Forecast Period (2026-2036), Driven by Novel Therapies and Expanding Treatment Landscape | DelveInsight - PR Newswire
IOVA Stock Price, Quote & Chart - ChartMill
Iovance Biotherapeutics (IOVA) Could Be 76% Undervalued Following Its Refreshed Growth Narrative - Sahm
Iovance Biotherapeutics (IOVA) Updates its Corporate Presentation, Here’s What’s Important to Note - Insider Monkey
Heartflow vs. Iovance Biotherapeutics: Which Healthcare Stock Is a Better Buy in 2026? - AOL.com
This Stock Is Up 74% This Year: Is It Too Late to Buy? - The Motley Fool
Enterprise value to revenue forward of Iovance Biotherapeutics, Inc. – NASDAQ:IOVA - TradingView
Iovance Biotherapeutics Inc Azioni (IOVA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Iovance Biotherapeutics Inc Azioni (IOVA) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| GRAF FINCKENSTEIN FRIEDRICH | Chief Medical Officer |
Jun 05 '26 |
Option Exercise |
0.00 |
7,813 |
0 |
144,087 |
| Puri Raj K. | Chief Regulatory Officer |
Jun 05 '26 |
Option Exercise |
0.00 |
9,766 |
0 |
251,957 |
| BILINSKY IGOR | Chief Operating Officer |
Jun 05 '26 |
Option Exercise |
0.00 |
7,813 |
0 |
137,896 |
| Vogt Frederick G | Interim CEO & General Counsel |
Jun 01 '26 |
Option Exercise |
0.00 |
41,668 |
0 |
571,206 |
| Puri Raj K. | Chief Regulatory Officer |
Jun 01 '26 |
Option Exercise |
0.00 |
5,469 |
0 |
244,699 |
| GRAF FINCKENSTEIN FRIEDRICH | Chief Medical Officer |
Jun 01 '26 |
Option Exercise |
0.00 |
8,790 |
0 |
140,747 |
| BILINSKY IGOR | Chief Operating Officer |
Jun 01 '26 |
Option Exercise |
0.00 |
8,790 |
0 |
134,556 |
| Kirby Daniel Gordon | Chief Commercial Officer |
May 11 '26 |
Option Exercise |
0.00 |
10,000 |
0 |
149,381 |
| Vogt Frederick G | Interim CEO & General Counsel |
Mar 05 '26 |
Option Exercise |
0.00 |
62,493 |
0 |
556,293 |
| GRAF FINCKENSTEIN FRIEDRICH | Chief Medical Officer |
Mar 05 '26 |
Option Exercise |
0.00 |
31,246 |
0 |
148,477 |
2.44%
0.02%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):